Bone Biologics Q3 2026 Results: Net Loss of $618K, Loss Narrows
Bone Biologics Corp reported a net loss of $2,157,341 for the nine months ended September 30, 2026, compared to a loss of $2,424,348 in the prior year period. The company remains in the development stage with zero revenue, focusing its expenditures on research and development for its NELL-1/DBM product candidate.
- Key figure
- Net loss $618K